Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada
Provided By GlobeNewswire
Last update: Mar 25, 2025
Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace
Read more at globenewswire.comNASDAQ:MGRX (11/5/2025, 10:38:45 AM)
1.8
0 (0%)
Find more stocks in the Stock Screener
MGRX Latest News and Analysis
